| 190 | 0 | 54 |
| 下载次数 | 被引频次 | 阅读次数 |
为研究MG132对不同毒力狂犬病病毒（Rabies virus,RABV）的体外抑制作用，本实验运用CCK8的方法评价MG132的细胞毒性，用直接免疫荧光（Direct immunofluorescence,DFA）、半数组织培养感染剂量法（TCID50）和qRT-PCR等方法分析MG132对RABV的体外抑制作用并以利巴韦林和法匹拉韦（Favipiravir,T-705）作为阳性对照评价MG132体外抑制RABV的效果。结果表明CVS-11及SC16感染N2a和BSR细胞后加入5μmol/L MG132均可在体外抑制CVS-11及SC16的复制，其中预加药2h以内没有抑制CVS-11及SC16复制的效果，但后加药1～24h均可抑制CVS-11及SC16的体外复制，并且感染后1h加药能达到与阳性对照利巴韦林相似的抑制效果且效果优于T-705。因此感染后添加MG132可以在体外有效抑制RABV的复制。
Abstract：To investigate the inhibitory effect of MG132 on rabies virus(RABV) strains with varying virulence in vitro, this study first evaluated the cytotoxicity of MG132 using the Cell Counting Kit-8(CCK-8) assay. The antiviral effects of MG132 against RABV were assessed by direct immunofluorescence assay(DFA), median tissue culture infectious dose(TCID50), and quantitative real-time PCR(qRT-PCR). Ribavirin and favipiravir(T-705) were included as positive controls. The results showed that treatment with 5 μmol/L MG132effectively inhibited the replication of both CVS-11 and SC16 strains in N2a and BSR cells. Pre-treatment with MG132 up to 2 hours before viral infection did not affect viral replication, whereas post-treatment within 1 to 24hours after infection significantly suppressed viral replication. Notably, treatment with MG132 at 1 hour postinfection exhibited an inhibitory effect comparable to that of ribavirin and superior to T-705. These findings suggest that MG132 can effectively inhibit the replication of RABV in vitro when administered after infection, providing a potential avenue for antiviral intervention.
[1] Hemachudha T, Ugolini G, Wacharapluesadee S, et al. Human rabies:neuropathogenesis, diagnosis, and management[J]. Lancet Neurol, 2013, 12(5):498-513. DOI:10. 1016/s1474-4422(13)70038-3.
[2] Huang Y, Jiao S, Tao X, et al. Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection[J]. J Neuroinflammation, 2014, 11:146.DOI:10. 1186/s12974-014-0146-y.
[3] Singh R, Singh KP, Cherian S, et al. Rabiesepidemiology, pathogenesis, public health concerns and advances in diagnosis and control:a comprehensive review[J]. Vet Q, 2017, 37(1):212-251. DOI:10. 1080/01652176. 2017. 1343516.
[4] Appolinario CM, Jackson AC. Antiviral therapy for human rabies[J]. Antivir Ther, 2015, 20(1):1-10.DOI:10. 3851/imp2851.
[5] Banyard AC, Mansfield KL, Wu G, et al. Reevaluating the effect of Favipiravir treatment on rabies virus infection[J]. Vaccine, 2019, 37(33):4686-4693.DOI:10. 1016/j. vaccine. 2017. 10. 109.
[6] Smith TG, Jackson FR, Morgan CN, et al. Antiviral ranpirnase TMR-001 inhibits rabies virus release and cell-to-cell infection in vitro[J]. Viruses, 2020, 12(2):177. DOI:10. 3390/v12020177.
[7] Tu Z, Gong W, Zhang Y, et al. Inhibition of rabies virus by 1, 2, 3, 4, 6-penta-O-galloyl-β-d-glucose involves mTOR-dependent autophagy[J]. Viruses,2018, 10(4):201. DOI:10. 3390/v10040201.
[8]迟瑛琳，刘铮然，谢渊，等.瑞德西韦对狂犬病病毒的体外抑制作用研究[J].中国人兽共患病学报，2022,38(12):1063-1071.
[9]谢渊，迟瑛琳，陶晓燕，等.加利地韦对狂犬病病毒体外抑制作用研究[J].中国人兽共患病学报，2023, 39(12):1151-1157. DOI:10. 3969/j. issn. 1002-2694. 2023. 00. 149.
[10]Chi YL, Xie Y, Liu SQ, et al. Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro[J]. Virol J, 2023, 20(1):258.DOI:10. 1186/s12985-023-02213-w.
[11]何晴，刘铮然，刘茜，等. T-2毒素对狂犬病病毒体外复制的抑制作用研究[J].病毒学报，2022, 38(5):1060-1068.DOI:10. 13242/j.cnki.bingduxuebao. 004209.
[12]Zhao J, Wang Q, Liu Z, et al. Z-Ligustilide restricts rabies virus replication by inducing ferroptosis through the ACSL4-LPCAT3-POR pathway[J]. Vet Microbiol, 2024, 298:110260. DOI:10. 1016/j.vetmic. 2024. 110260.
[13]Konishi K, Kusakabe S, Kawaguchi N, et al. β-d-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus[J].Antiviral Res, 2024, 229:105977. DOI:10. 1016/j.antiviral. 2024. 105977.
[14]Chen Y, Fan S, Zhao M, et al. MG132 attenuates the replication of classical swine fever virus in vitro[J].Front Microbiol, 2020, 11:852. DOI:10. 3389/fmicb. 2020. 00852.
[15]Jiang X, Kanda T, Wu S, et al. Hepatitis C virus nonstructural protein 5A inhibits MG132-induced apoptosis of hepatocytes in line with NF-κB-nuclear translocation[J]. PLoS One, 2015, 10(7):e0131973.DOI:10. 1371/journal. pone. 0131973.
[16]Xu L, Zhou X, Peppelenbosch MP, et al. Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific[J]. Arch Virol, 2015, 160(2):435-439.DOI:10. 1007/s00705-014-2303-0.
[17]Wu X, Zheng Y, Liu M, et al. BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains[J]. Autophagy, 2021, 17(8):1934-1946. DOI:10. 1080/15548627. 2020. 1802089.
[18]Guo L, Zhang D, Ren X, et al. SYVN1 attenuates ferroptosis and alleviates spinal cord ischemiareperfusion injury in rats by regulating the HMGB1/NRF2/HO-1 axis[J]. Int Immunopharmacol, 2023,123:110802. DOI:10. 1016/j. intimp. 2023. 110802.
[19]Xie Y, Chi YL, Liu SQ, et al. BCX4430 inhibits the replication of rabies virus by suppressing mTORdependent autophagy invitro[J]. Virology, 2023, 585:21-31. DOI:10. 1016/j. virol. 2023. 05. 012.
[20]于鹏程，闫江泓，吴未辰，等.狂犬病病毒中和抗体检测试剂盒的效果评价[J].国际检验医学杂志，2016,37(23):3331-3332. DOI:10. 3969/j. issn. 1673-4130. 2016. 23. 035.
[21]陈柯君，李佳，邓乐君，等.反复冻融次数和不同保存温度对病毒滴度的影响[J].动物医学进展，2018, 39(2):61-65.
[22]Anindita PD, Sasaki M, Okada K, et al. Ribavirinrelated compounds exert in vitro inhibitory effects toward rabies virus[J]. Antiviral Res, 2018, 154:1-9.DOI:10. 1016/j. antiviral. 2018. 03. 011.
[23]Yamada K., et al., Efficacy of favipiravir(T-705)in rabies postexposure prophylaxis[J]. Infect Dis, 2016.213(8):p. 1253-61. DOI:10. 1093/infdis/jiv586
[24]World Health Organization. WHO expert consultation on rabies. Second report. World Health Organ Tech Rep Ser. 2013;(982):1-139, back cover. PMID:24069724.
[25] Lacy M, Phasuk N, Scholand SJ.Human rabies treatment-from palliation to promise[J].Viruses, 2024, 16(1):160. DOI:10. 3390/v16010160.
[26]Guo N, Peng Z. MG132, a proteasome inhibitor,induces apoptosis in tumor cells[J]. Asia-Pac J Clncl Oncology, 2013, 9(1):6-11. DOI:10. 1111/j. 1743-7563. 2012. 01535. x.
[27]Madelain V, Duthey A, MentréF, et al. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human Primates[J]. Antiviral Res, 2020,177:104758. DOI:10. 1016/j. antiviral. 2020. 104758.
[28]Westover JB, Sefing EJ, Bailey KW, et al. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses[J]. Antiviral Res,2016, 126:62-68.DOI:10. 1016/j.antiviral. 2015. 12. 006.
[29]Madelain V, MentréF, Baize S, et al. Modeling favipiravir antiviral efficacy against emerging viruses:from animal studies to clinical trials[J]. CPT Pharmacometrics Syst Pharmacol, 2020, 9(5):258-271. DOI:10. 1002/psp4. 12510.
[30]Ujino S, Yamaguchi S, Shimotohno K, et al.Combination therapy for hepatitis C virus with heatshock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132[J]. Antivir Chem Chemother, 2010,20(4):161-167. DOI:10. 3851/imp1479.
[31]Liu X, Meng L, Li X, et al. Regulation of FN1degradation by the p62/SQSTM1-dependent autophagylysosome pathway in HNSCC[J]. Int J Oral Sci, 2020,12(1):34. DOI:10. 1038/s41368-020-00101-5.
[32]Harhouri K, Navarro C, Depetris D, et al. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation[J]. EMBO Mol Med,2017, 9(9):1294-1313. DOI:10. 15252/emmm. 201607315.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.250138
中图分类号:R373.9
引用信息:
[1]迟瑛琳,杨诺,谢渊,等.MG132对狂犬病病毒体外抑制作用研究[J].病毒学报,2025,41(04):1131-1141.DOI:10.13242/j.cnki.bingduxuebao.250138.
基金信息:
中国疾病预防控制中心病毒病预防控制所青年科学基金（项目号：IVDC-202402）,题目：狂犬病病毒通过自噬蛋白Beclin1调控TLR7-MyD88-NF-κB炎症应答通路的机制~~
2025-04-16
2025
2025-05-20
2025-07-29
2025
1
2025-07-04
2025-07-04
2025-07-04